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Introduction {#sec001}
============

In the late 1990s, advances in metallurgy and tribology led to a renewed interest in the use of metal-on-metal (MoM) bearings in total hip replacements (THR) \[[@pone.0147872.ref001]\]. The use of large diameter (LD) femoral heads that mimick the native anatomy of the hip joint requires relatively thin, i.e., 4--8 mm acetabular components to prevent excessive acetabular bone resection. Due to the extreme hardness of the new cobalt-chrome alloy Metasul, it became possible to manufacture these thin acetabular components \[[@pone.0147872.ref001]\]. With improved fixation techniques, the concept of large-headed femoral components coupled with thin monoblock cups were rapidly adopted for MoM hip resurfacings. Preliminary results with these second generation MoM hip resurfacings were excellent, and the number of hip resurfacings surged in the early 2000s. Later on, LD MoM bearings for cementless stemmed THRs were adopted.

It was only after a decade of use of these contemporary MoM bearings that adverse reaction to metal debris (ARMD) came into focus \[[@pone.0147872.ref002],[@pone.0147872.ref003]\]. Metal debris caused by the increased wear of the bearing and/or the corrosion in the neck-head taper in a stemmed MoM THR leads to local soft tissue reactions that include synovitis, necrosis and extra-articular cysts or solid masses, i.e., pseudotumours \[[@pone.0147872.ref004]--[@pone.0147872.ref008]\]. ARMD is an umbrella term proposed by Langton et al. in 2010 to describe all the microscopic and macroscopic findings **t**hat were seen in revision surgeries performed on patients with MoM hip replacements who suffered from unexplained pain \[[@pone.0147872.ref002]\].

Nowadays, revision surgery is considered if a large thick-walled pseudotumour is seen in MRI, or if extremely high metal ion levels (\>10--20 ppb) are found in the serum or whole blood (WB). Prior to 2010, MoM hip resurfacings and modular MoM THRs produced excellent results in young and active patients. Since 2010, however, there has been a drastic decline in the use of MoM hip replacements due to the higher than anticipated prevalence of ARMD and subsequent high failure rates \[[@pone.0147872.ref009],[@pone.0147872.ref010]\].

An extensive amount of research has been published on ARMD. Novel screening methods such as blood metal ion measurement and cross-sectional imaging have offered the profound possibility to investigate the etiopathogenesis, clinical history and clinical manifestation of ARMD \[[@pone.0147872.ref002],[@pone.0147872.ref004],[@pone.0147872.ref005],[@pone.0147872.ref011]--[@pone.0147872.ref014]\]. Both blood metal ion measurement and cross-sectional imaging have been proven to be useful in the diagnostics of ARMD \[[@pone.0147872.ref004],[@pone.0147872.ref005],[@pone.0147872.ref015]\]. However, there is a paucity of current literature regarding the usefulness of systematic screening for ARMD. Current guidelines on how to follow-up patients with MoM hip replacements lack sufficient evidence \[[@pone.0147872.ref016]--[@pone.0147872.ref018]\]. The intensity and coverage of such screening is strongly associated with the costs related to the surveillance of patients with MoM hip replacements.

Although the number of patients receiving MoM THRs has decreased drastically in recent years,. there are still a vast number of patients with MoM hip replacement still *in situ*. Thus, there is a clear need for sufficient evidence on how to manage patients with MoM hip replacements.

The aim of this study was to conduct a systematic review and meta-analysis of current literature to establish the prevalence of revision confirmed ARMD stratified by the use of different screening protocols. A second aim was to explore the possible confounding effects of follow-up time and year of publication of the study on the prevalence of revision confirmed ARMD by performing a meta-regression analysis.

Methods {#sec002}
=======

Eligibility criteria {#sec003}
--------------------

A study was deemed eligible for our analysis if 1) it included an original patient cohort operated on with a single disclosed implant, 2) the implant used in the study was MoM hip resurfacing or MoM THR with a femoral head diameter of 36 mm or larger, and 3) the reasons for the revisions were clearly stated or the operative findings in the revision surgery were outlined. An original patient cohort means a clearly defined population of patients operated on with a certain implant within a certain time interval at disclosed hospital(s). A study was excluded if more than one implant was used and the number of patients for each implant was not given. Moreover, a study was excluded if 1) it included patients referred from elsewhere to the place where the study was carried out (violation of eligibility criteria 1), 2) more than one implant was used, but revisions were not stratified according to the implant used, 3) the reasons for all revisions were not given, 4) the size of a study arm for a single implant was less than 20 hips.

Furthermore, if a study included a study arm or a subcohort of a study arm, which had been included in a previous study and in both studies a similar screening method was used, the more recent study was included in our analysis. However, if the two studies included an identical study arm or a subcohort of a study arm but the more recent study implemented a different level of screening, both studies were included in our analyses since the primary aim of our study was to investigate the effect of screening levels on the prevalence of revision confirmed ARMD.

Information sources and search strategy {#sec004}
---------------------------------------

The review was done according to PRISMA checklist ([S1 Checklist](#pone.0147872.s001){ref-type="supplementary-material"}). We developed a search strategy that was implemented in the PubMed and Scopus databases. Since our objective was to establish a pooled prevalence of ARMD seen with contemporary MoM hip replacements, we started our search of these databases from the year 1995. The search was conducted in May 2015.

We performed two searches of these two databases. The following search strategy was used first: "(metal-on-metal AND hip) OR ((\"hip resurfacing\" OR (\"surface replacement\" AND hip) OR \"large-diameter total hip\") NOT (metal-on-metal))". A second search was carried out afterwards that was combined with the first search using the Boolean operator NOT in order to remove duplicates: "((recap AND hip) OR (magnum AND hip) OR (cormet AND hip) OR (durom AND hip) OR (conserve AND hip) OR (pinnacle AND hip) OR (asr AND hip) OR (m2a AND hip) OR (birmingham AND hip) OR (mitch AND hip) OR (adept AND hip))". The latter search phrase outlines the most commonly used MoM hip replacement brand names.

Study selection {#sec005}
---------------

All the records retrieved from the two databases using our search strategy were screened. An assessment of duplicate references was not performed. Abstracts of all the records were assessed. Studies that outlined the use of any "metal-on-metal" hip implant or a hip implant by a brand name along with any clinical outcome (patient reported outcome score, survival rate, failure rate, complication rate, revision rate, deaths, levels of metal ion levels, cross-sectional imaging findings) were selected for eligibility assessment. All the studies meeting our eligibility criteria were selected for both systematic review and meta-analysis that was conducted using the metaregression technique.

Data extraction {#sec006}
---------------

The number of hips operated on with each given implant was recorded. Implant concept and publication year of the study were also recorded. Three categories for implant concept were used: 1) hip resurfacings or surface arthroplasties, 2) LD MoM THRs (femoral diameter \>44 mm), which comprise identical bearing systems as in hip resurfacings coupled with a mainly cementless stem, and 3) MoM THR with a femoral diameter of 44 mm or smaller \[medium-diameter (MD) MoM THR\]. The last group included two fixed-sized MoM THRs: the Pinnacle 36 mm MoM THR and the M2a-38 MoM THR with a 38 mm femoral diameter. Small-diameter (\<36 mm) MoM hip replacements were not included in the present study. Two studies included patients operated on with a Birmingham Mid-Head Resection (BMHR) device. These were included in the hip-resurfacing group due to their similarity. Follow-up time was recorded. We did not differentiate between mean and median follow-up times. The use of metal ion level measurement in serum or WB was assessed as well as the use of any cross-sectional imaging modality. In short, five levels of screening were identified: no screening (level 0), targeted blood metal ion measurement and/or cross-sectional imaging (level 1), blood metal ion measurement without imaging (level 2), blood metal ion measurement with targeted imaging (level 3) and comprehensive screening (both blood metal ions and imaging for all; level 4). If neither screening method was used, the level of screening was labeled "None" (Level 0). If prerevision details that included metal ion levels and/or imaging findings were described in single patients in the results section, the use of screening was considered lacking unless there was a protocol rationale in methods section that described the use of these screening methods, i.e., patients with a complaint underwent an MRI scan. If blood metal ion measurements were performed in a subset of patients and no cross-sectional imaging was performed or if cross-sectional imaging was performed in a subset of patients without any given metal ion data, the level of screening was labeled "Targeted CoCr and/or imaging" (Level 1). Again, if prerevision imaging findings or metal ion levels were described in single patients without any protocol rationale detailed in the methods section, these screening methods were considered to be lacking. If all patients underwent a metal ion measurement without any imaging protocol outlined in the methods section, the level of screening was labeled "CoCr without imaging" (Level 2). If targeted imaging was used along with a routine (full coverage) metal ion measurement, the level of screening was labeled "CoCr with targeted imaging" (Level 3). If all patients underwent both metal ion measurement and cross-sectional imaging, the level of screening was labeled "Comprehensive" (Level 4). The modality of the imaging was recorded. We did not differentiate between serum and WB measurements.

The number and reasons for the revisions were recorded. Detailed prerevision and perioperative findings were assessed if described. The following reasons for the revision were considered to be ARMD: "ARM(e)D", "Adverse wear","adverse local tissue reaction (ALTR)","adverse tissue reaction (ATR)", "metallosis", "pseudotumour" and "synovitis". "Elevated metal ion levels" or "component/cup malposition" as reasons for revision were not considered to be ARMD unless perioperative findings were described. The definition of ARMD was also met if perioperative findings were described, that is if the operative findings described included the terms "metallosis", "synovitis", "pseudotumour", "necrotic substance/tissue" and the case(s) outlined were considered to have failed due to ARMD. Cases with ARMD as revision indication but that also included a clear statement about component loosening were not included in our analyses.

Summary measures {#sec007}
----------------

The primary summary measure was the prevalence of ARMD. This was calculated by dividing the total number of revisions due to ARMD by the total number of hips included in the study. Confounding variables included in the meta-regression were follow-up time, year of publication and level of screening. This information was extracted as described in the previous section.

Data synthesis {#sec008}
--------------

The Q-statistic was used to assess heterogeneity across the studies. If the Q-statistic suggested high heterogeneity (p-value\< 0.1), a random effects model was used instead of a fixed effects model. The amount of heterogeneity was assessed using the I^2^-measure. The DerSimonian-Laird estimator was used as a random effects model when needed. Arcsine transformation was used for the summary measure (prevalence o revision confirmed ARMD). We preferred this to logit transformation because zero prevalence was overrepresented in our study. With logit transformation we would have been obliged to choose a random increment to be added to the zero summary measures. We would not have had any reasonable value for this. Metaregression analysis was used to assess whether differences in the prevalence of revision confirmed ARMD across different levels of screening remained after adjusting for the year of publication and follow-up time. All analyses were stratified by the implant concept (HR/LD THR/MD THR). Finally, we carried out a "best case" sensitivity analysis by performing all the aforementioned analyses using only study arms with patients operated on with Birmingham Hip Resurfacing (BHR, Smith&Nephew, Warwick, United Kingdom).

Results {#sec009}
=======

A PRISMA flow diagram of the study selection process is shown in [Fig 1](#pone.0147872.g001){ref-type="fig"}. In total, 122 studies were included. These studies comprised 145 study arms ([Table 1](#pone.0147872.t001){ref-type="table"}) ([S1 Datafile](#pone.0147872.s002){ref-type="supplementary-material"}). The median number of hips in the study arms was 128 (range 20--3095). The most commonly used implant was BHR ([Table 2](#pone.0147872.t002){ref-type="table"}). Patients in 48 study arms were operated on with BHR. In total, 100 study arms included patients operated on with a hip-resurfacing device \[[@pone.0147872.ref014],[@pone.0147872.ref015],[@pone.0147872.ref019]--[@pone.0147872.ref099]\]. Thirty-three study arms included patients with LD-THA \[[@pone.0147872.ref035],[@pone.0147872.ref056],[@pone.0147872.ref079],[@pone.0147872.ref095],[@pone.0147872.ref100]--[@pone.0147872.ref121]\]. The most commonly used LD THA was the articular surface replacement (ASR) XL THR (DePuy Orthopedics, Warsaw, IN, USA). In general, the stems used with LD MoM bearing couples varied greatly. MD THR was used in 11 study arms \[[@pone.0147872.ref094],[@pone.0147872.ref112],[@pone.0147872.ref120],[@pone.0147872.ref122]--[@pone.0147872.ref129]\]. In most of the studies, a traditional or conventional follow-up protocol without metal ion measurement and cross-sectional imaging was used ([Table 2](#pone.0147872.t002){ref-type="table"}). Distribution of the follow-up time and year of publication are presented in [Table 2](#pone.0147872.t002){ref-type="table"}.

![Flow chart of the study selection.](pone.0147872.g001){#pone.0147872.g001}
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###### Details of the study arms.

Within implant concept, study arms are primarily ordered by brand name, secondarily by screening level.

![](pone.0147872.t001){#pone.0147872.t001g}

  Study                                                       Patients   Hips   Acetabular side     Femoral side                                                                                                        Metal ion measurement   Targeted measurement performed                                           Cross-sectional imaging   Targeted imaging                                                                        Imaging modality   Level of screening   Follow-up in years   Revisions due to ARMD   Prevalence of ARMD
  ----------------------------------------------------------- ---------- ------ ------------------- ------------------------------------------------------------------------------------------------------------------- ----------------------- ------------------------------------------------------------------------ ------------------------- --------------------------------------------------------------------------------------- ------------------ -------------------- -------------------- ----------------------- --------------------
  Hip resurfacings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Bergeron et al. 2009 \[[@pone.0147872.ref025]\]             209        228    ASR                 ASR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    2.9                  0                       0.000
  Jameson et al. \[[@pone.0147872.ref051]\]                   192        214    ASR                 ASR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    3.6                  6                       0.028
  Malhotra et al. 2012 \[[@pone.0147872.ref060]\]             23         32     ASR                 ASR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    3.6                  0                       0.000
  Siebel et al. 2006                                          300        300    ASR                 ASR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    0.56                 0                       0
  Whitehouse et al. 2013 \[[@pone.0147872.ref094]\]           0          76     ASR                 ASR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    4.9                  4                       0.053
  Kadar et al. 2013 \[[@pone.0147872.ref053]\]                125        139    ASR                 ASR                                                                                                                 Target                  Symptoms, suboptimal cup position, small femoral size, surgeon concern   Target                    Symptoms, suboptimal cup position, small femoral size, surgeon concern                  MRI                1                    3.5                  1                       0.007
  Whitwell et al. 2012 (Arm 1) \[[@pone.0147872.ref095]\]     0          21     ASR                 ASR                                                                                                                 Target                  Patients with symptoms                                                   Target                    Patients with symptoms                                                                  US                 1                    5.2                  3                       0.143
  Isaac et al. 2009 \[[@pone.0147872.ref136]\]                0          77     ASR                 ASR                                                                                                                 All                                                                                              No                                                                                                                No                 2                    2.0                  0                       0.000
  Langton 2011a (Arm 1) \[[@pone.0147872.ref014]\]            0          59     ASR                 ASR                                                                                                                 All                                                                                              No                                                                                                                No                 2                    2.6                  2                       0.034
  Langton 2011a (Arm 4) \[[@pone.0147872.ref014]\]            0          430    ASR                 ASR                                                                                                                 All                                                                                              No                                                                                                                No                 2                    3.1                  27                      0.063
  Shemesh et al. 2014 \[[@pone.0147872.ref083]\]              0          49     ASR                 ASR                                                                                                                 All                                                                                              No                                                                                                                No                 2                    4.1                  0                       0.000
  Fernandez et al. 2014 (Arm 1) \[[@pone.0147872.ref035]\]    0          60     ASR                 ASR                                                                                                                 All                                                                                              Target                                                                                                            CT                 3                    2.9                  2                       0.033
  Reito et al. 2013 (Arm 1) \[[@pone.0147872.ref079]\]        142        168    ASR                 ASR                                                                                                                 All                                                                                              All                                                                                                               MRI                4                    5.3                  42                      0.250
  Aulakh et al. 2010 (Arm 1) \[[@pone.0147872.ref021]\]       95         101    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    3.0                  0                       0.000
  Aulakh et al. 2010 (Arm 2) \[[@pone.0147872.ref021]\]       97         101    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    2.0                  0                       0.000
  Azam et al. 2015 \[[@pone.0147872.ref022]\]                 222        224    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    12.1                 4                       0.018
  Baker et al. 2011 \[[@pone.0147872.ref023]\]                0          63     BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    9.0                  0                       0.000
  Bose et al. 2010 \[[@pone.0147872.ref028]\]                 71         96     BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    5.4                  0                       0.000
  Coulter et al. 2012 \[[@pone.0147872.ref029]\]              213        230    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    10.4                 3                       0.013
  De Smet 2005 \[[@pone.0147872.ref032]\]                     0          252    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    2.8                  0                       0.000
  Della Valle et al. 2009 \[[@pone.0147872.ref033]\]          0          537    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    0.9                  0                       0.000
  Delport et al. 2011 (Arm 1) \[[@pone.0147872.ref034]\]      28         28     BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    4.8                  0                       0.000
  Fink Barnes et al. 2014 \[[@pone.0147872.ref036]\]          80         89     BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    3.6                  0                       0.000
  Giannini et al. 2011 \[[@pone.0147872.ref038]\]             134        142    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    6.1                  0                       0.000
  El Hachmi et al. 2014 \[[@pone.0147872.ref043]\]            141        151    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    4.2                  0                       0.000
  Heilpern et al. 2008 \[[@pone.0147872.ref046]\]             98         110    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    5.9                  0                       0.000
  Khan et al. 2009 \[[@pone.0147872.ref054]\]                 653        679    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    6.0                  1                       0.001
  Madhu et al. 2011 \[[@pone.0147872.ref059]\]                104        120    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    7.0                  0                       0.000
  Marulanda et al. 2008 \[[@pone.0147872.ref137]\]            0          230    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    1.30                 0                       0
  McAndrew et al. 2007 \[[@pone.0147872.ref062]\]             155        180    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    2.6                  0                       0.000
  McBryde et al. 2010 \[[@pone.0147872.ref063]\]              1826       2123   BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    3.5                  0                       0.000
  McMinn et al. 2011b \[[@pone.0147872.ref065]\]              0          3095   BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    8.0                  10                      0.003
  Naal et al. 2009 \[[@pone.0147872.ref138]\]                 0          22     BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    3.6                  0                       0.000
  Ollivere et al. 2008 \[[@pone.0147872.ref071]\]             0          463    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    3.6                  7                       0.015
  Pailhe et al. 2013 (Arm 2) \[[@pone.0147872.ref072]\]       0          42     BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    3.2                  0                       0.000
  Patel et al. 2014 \[[@pone.0147872.ref074]\]                85         109    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    5.2                  0                       0.000
  Rahman et al. 2010 \[[@pone.0147872.ref077]\]               302        329    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    5.0                  1                       0.003
  Reito et al. 2011 \[[@pone.0147872.ref078]\]                126        144    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    6.0                  2                       0.014
  Sandiford et al. 2014 \[[@pone.0147872.ref082]\]            107        109    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    8.2                  3                       0.028
  Swank et al. 2009 \[[@pone.0147872.ref087]\]                0          128    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    2.0                  0                       0.000
  Takamura et al. 2014 (Arm 1) \[[@pone.0147872.ref088]\]     0          115    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    2.8                  2                       0.017
  Takamura et al. 2014 (Arm 2) \[[@pone.0147872.ref088]\]     0          236    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    2.2                  1                       0.004
  Whitehouse et al. 2013 \[[@pone.0147872.ref139]\]           0          103    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    4.3                  4                       0.039
  Witzleb et al. 2008                                         263        300    BHR                 BHR                                                                                                                 No                                                                                               No                                                                                                                No                 0                    2.00                 0                       0
  Murray et al. 2012 \[[@pone.0147872.ref066]\]               554        646    BHR                 BHR                                                                                                                 No                                                                                               Target                    OHS\<33                                                                                 MRI                1                    8.0                  26                      0.040
  Holland et al. 2012 \[[@pone.0147872.ref047]\]              90         100    BHR                 BHR                                                                                                                 Target                                                                                           No                                                                                                                No                 1                    9.6                  2                       0.020
  Kostensalo et al. 2014 (Arm 1) \[[@pone.0147872.ref056]\]   0          249    BHR                 BHR                                                                                                                 Target                  ns                                                                       No                                                                                                                No                 1                    6.2                  3                       0.012
  Nam et al. 2012 (Arm 2) \[[@pone.0147872.ref069]\]          126        137    BHR                 BHR                                                                                                                 Target                  ns                                                                       No                                                                                                                No                 1                    5.7                  2                       0.015
  Pailhe et al. 2014 \[[@pone.0147872.ref073]\]               162        180    BHR                 BHR                                                                                                                 Target                  Patient with symptoms                                                    No                                                                                                                No                 1                    6.0                  1                       0.006
  Daniel et al. 2014 \[[@pone.0147872.ref031]\]               886        1000   BHR                 BHR                                                                                                                 Target                  Patients with longest follow-up                                          Target                    Patients with longest follow-up                                                         CT                 1                    13.7                 7                       0.007
  Langton 2011a (Arm 2) \[[@pone.0147872.ref014]\]            0          1922   BHR                 BHR                                                                                                                 All                                                                                              No                                                                                                                No                 2                    5.7                  23                      0.012
  Langton 2011a (Arm 5) \[[@pone.0147872.ref014]\]            0          180    BHR                 BHR                                                                                                                 All                                                                                              No                                                                                                                No                 2                    5.4                  1                       0.006
  Langton 2011a (Arm 6) \[[@pone.0147872.ref014]\]            0          674    BHR                 BHR                                                                                                                 All                                                                                              No                                                                                                                No                 2                    5.4                  3                       0.004
  Robinson et al. 2014 (Arm 1) \[[@pone.0147872.ref081]\]     0          120    BHR                 BHR                                                                                                                 All                                                                                              No                                                                                                                No                 2                    4.2                  1                       0.008
  Su et al. 2014 \[[@pone.0147872.ref086]\]                   265        293    BHR                 BHR                                                                                                                 All                                                                                              No                                                                                                                No                 2                    3.6                  1                       0.003
  van der Straeten et al. 2013 \[[@pone.0147872.ref089]\]     232        250    BHR                 BHR                                                                                                                 All                                                                                              No                                                                                                                No                 2                    10.8                 4                       0.016
  Hartmann et al. 2012 \[[@pone.0147872.ref045]\]             95         100    BHR                 BHR                                                                                                                 All                                                                                              Target                    Co or Cr level \>10 ppb                                                                 CT                 3                    10.0                 3                       0.030
  Reito et al. 2014 \[[@pone.0147872.ref015]\]                219        261    BHR                 BHR                                                                                                                 All                                                                                              Target                    Patients with symptoms, Co or Cr level \>5 ppb                                          US/MRI             3                    10.4                 11                      0.042
  Bisschop et al. 2013 \[[@pone.0147872.ref026]\]             129        149    BHR                 BHR                                                                                                                 All                                                                                              All                                                                                                               CT                 4                    3.4                  8                       0.054
  Haddad et al. 2015                                          40         47     BHR                 BHR                                                                                                                 All                                                                                              All                                                                                                               MRI                1                    12.1                 0                       0.000
  Junnila et al. 2015 \[[@pone.0147872.ref052]\]              32         42     BHR                 BHR                                                                                                                 All                                                                                              All                                                                                                               MRI                4                    6.7                  4                       0.095
  Radtke et al. 2014 \[[@pone.0147872.ref075]\]               75         85     Bionic              Bionic                                                                                                              No                                                                                               No                                                                                                                No                 0                    5.0                  0                       0.000
  McMinn et al. 2011a \[[@pone.0147872.ref140]\]              164        171    BMHR                BMHR                                                                                                                No                                                                                               No                                                                                                                No                 0                    3.5                  0                       0.000
  Rahman et al. 2011 \[[@pone.0147872.ref076]\]               34         35     BMHR                BMHR                                                                                                                No                                                                                               No                                                                                                                No                 0                    2.8                  0                       0.000
  Amstutz et al. 2011                                         0          1107   Conserve+           Conserve+                                                                                                           No                                                                                               No                                                                                                                No                 0                    6.8                  3                       0.003
  Arndt et al. 2013 \[[@pone.0147872.ref020]\]                0          55     Conserve+           Conserve+                                                                                                           No                                                                                               No                                                                                                                No                 0                    4.2                  0                       0.000
  Kim et al. 2008 \[[@pone.0147872.ref024]\]                  0          200    Conserve+           Conserve+                                                                                                           No                                                                                               No                                                                                                                No                 0                    2.6                  0                       0.000
  Fowble et al. 2009 \[[@pone.0147872.ref141]\]               50         50     Conserve+           Conserve+                                                                                                           No                                                                                               No                                                                                                                No                 0                    3.2                  0                       0.000
  Glyn-Jones et al. 2009 (Arm 1) \[[@pone.0147872.ref039]\]   0          606    Conserve+           Conserve+                                                                                                           No                                                                                               No                                                                                                                No                 0                    4.0                  8                       0.013
  Marker et al. 2010 \[[@pone.0147872.ref061]\]               0          361    Conserve+           Conserve+                                                                                                           No                                                                                               No                                                                                                                No                 0                    4.9                  0                       0.000
  McGrath et al. 2008 (Arm 1) \[[@pone.0147872.ref064]\]      0          42     Conserve+           Conserve+                                                                                                           No                                                                                               No                                                                                                                No                 0                    3.0                  0                       0.000
  McGrath et al. 2008 (Arm 2) \[[@pone.0147872.ref064]\]      0          153    Conserve+           Conserve+                                                                                                           No                                                                                               No                                                                                                                No                 0                    3.0                  0                       0.000
  Newman et al. 2008 \[[@pone.0147872.ref070]\]               120        126    Conserve+           Conserve+                                                                                                           No                                                                                               No                                                                                                                No                 0                    1.0                  0                       0.000
  Ribas et al. 2014 \[[@pone.0147872.ref080]\]                450        486    Conserve+           Conserve+                                                                                                           No                                                                                               No                                                                                                                No                 0                    7.2                  1                       0.002
  Wang et al. 2012 \[[@pone.0147872.ref080]\]                 34         37     Conserve+           Conserve+                                                                                                           No                                                                                               No                                                                                                                No                 0                    5.9                  0                       0.000
  Woon et al. 2013 \[[@pone.0147872.ref097]\]                 46         53     Conserve+           Conserve+                                                                                                           No                                                                                               No                                                                                                                No                 0                    8.3                  0                       0.000
  Zylberberg et al. 2015 \[[@pone.0147872.ref099]\]           458        548    Conserve+           Conserve+                                                                                                           No                                                                                               No                                                                                                                No                 0                    6.6                  4                       0.007
  Nam et al. 2012 (Arm 1) \[[@pone.0147872.ref069]\]          124        137    Conserve+           Conserve+                                                                                                           Target                  ns                                                                       No                                                                                                                No                 1                    5.5                  1                       0.007
  Bisseling et al. 2015 \[[@pone.0147872.ref027]\]            32         38     Conserve+           Conserve+                                                                                                           All                                                                                              No                                                                                                                No                 2                    4.8                  2                       0.053
  Kim et al. 2011 \[[@pone.0147872.ref142]\]                  97         97     Conserve+           Conserve+                                                                                                           All                                                                                              No                                                                                                                No                 2                    2.0                  0                       0.000
  Langton 2011a (Arm 3) \[[@pone.0147872.ref014]\]            0          961    Conserve+           Conserve+                                                                                                           All                                                                                              No                                                                                                                No                 2                    2.8                  4                       0.004
  Yang et al. 2011 \[[@pone.0147872.ref098]\]                 25         25     Conserve+           Conserve+                                                                                                           All                                                                                              No                                                                                                                No                 2                    2.0                  0                       0.000
  Stulberg et al. 2008 \[[@pone.0147872.ref085]\]             0          337    Cormet Hybrid       Cormet Hybrid                                                                                                       No                                                                                               No                                                                                                                No                 0                    2.0                  0                       0.000
  Gross et al. 2012 \[[@pone.0147872.ref040]\]                329        373    Cormet Uncemented   Cormet Cemented                                                                                                     No                                                                                               No                                                                                                                No                 0                    8.0                  2                       0.005
  Issa et al. 2013 \[[@pone.0147872.ref050]\]                 114        120    Cormet Uncemented   Cormet Cemented                                                                                                     No                                                                                               No                                                                                                                No                 0                    3.5                  0                       0.000
  Kordas et al. 2012                                          215        234    Cormet Uncemented   Cormet Cemented                                                                                                     No                                                                                               No                                                                                                                No                 0                    5.0                  0                       0.000
  Madadi et al. 2011 \[[@pone.0147872.ref058]\]               0          52     Cormet Uncemented   Cormet Cemented                                                                                                     No                                                                                               No                                                                                                                No                 0                    3.4                  0                       0.000
  Gross et al. 2008 \[[@pone.0147872.ref042]\]                18         20     Cormet Uncemented   Cormet Uncemented                                                                                                   No                                                                                               No                                                                                                                No                 0                    7.4                  0                       0.000
  Hull et al. 2011 \[[@pone.0147872.ref048]\]                 131        135    Cormet Uncemented   Cormet Uncemented                                                                                                   No                                                                                               No                                                                                                                No                 0                    2.9                  0                       0.000
  Leclerq et al. 2013 \[[@pone.0147872.ref057]\]              580        644    DUROM               DUROM                                                                                                               No                                                                                               No                                                                                                                No                 0                    2.8                  1                       0.002
  Naal et al. 2011 \[[@pone.0147872.ref067]\]                 91         100    DUROM               DUROM                                                                                                               No                                                                                               No                                                                                                                No                 0                    5.0                  0                       0.000
  Pailhe et al. 2013 (Arm 1) \[[@pone.0147872.ref072]\]       0          100    DUROM               DUROM                                                                                                               No                                                                                               No                                                                                                                No                 0                    3.2                  0                       0.000
  Vendittoli et al. 2013 \[[@pone.0147872.ref093]\]           0          112    DUROM               DUROM                                                                                                               Target                  Patients with follow-up of \>5 years                                     No                                                                                                                No                 1                    8.0                  1                       0.009
  Robinson et al. 2014 (Arm 2) \[[@pone.0147872.ref143]\]     0          240    DUROM               DUROM                                                                                                               All                                                                                              No                                                                                                                No                 2                    4.6                  0                       0.000
  van der Weegen et al. 2012 \[[@pone.0147872.ref091]\]       240        280    M2a-Magnum          ReCap                                                                                                               No                                                                                               Target                    Patients with symptoms                                                                  US                 1                    3.3                  0                       0.000
  van der Weegen et al. 2014 \[[@pone.0147872.ref090]\]       235        271    M2a-Magnum          ReCap                                                                                                               All                                                                                              All                                                                                                               MRI                4                    4.6                  9                       0.033
  Delport et al. 2011 (Arm 2) \[[@pone.0147872.ref034]\]      28         28     M2a-Magnum          ReCap                                                                                                               No                                                                                               No                                                                                                                No                 0                    1.4                  0                       0.000
  Glyn-Jones et al. 2009 (Arm 2) \[[@pone.0147872.ref039]\]   0          128    M2a-Magnum          ReCap                                                                                                               No                                                                                               No                                                                                                                No                 0                    4.0                  0                       0.000
  Gross et al. 2013 \[[@pone.0147872.ref041]\]                0          2166   M2a-Magnum          ReCap                                                                                                               Target                                                                                           Target                                                                                                            CT/MRI             1                    4.0                  5                       0.002
  Daniel et al. 2010 \[[@pone.0147872.ref030]\]               160        184    McMinn              McMinn                                                                                                              No                                                                                               No                                                                                                                No                 0                    10.6                 0                       0.000
  LD THR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Bolland et al. 2011 \[[@pone.0147872.ref102]\]              185        199    Adept/BHR           CPT                                                                                                                 All                                                                                              No                                                                                                                No                 2                    5.2                  14                      0.070
  Steele et al. 2008 \[[@pone.0147872.ref119]\]               109        120    ASR XL              ns                                                                                                                  No                                                                                               No                                                                                                                No                 0                    1.6                  4                       0.033
  Wynn-Jones et al. 2011 \[[@pone.0147872.ref121]\]           54         62     ASR XL              Corail                                                                                                              No                                                                                               All                                                                                                               MRI                1                    2.5                  7                       0.113
  Whitwell et al. 2012 (Arm 2) \[[@pone.0147872.ref095]\]     0          100    ASR XL              Corail                                                                                                              Target                  Patients with symptoms                                                   Target                    Patients with symptoms                                                                  US                 1                    4.4                  17                      0.170
  Hug et al. 2013 \[[@pone.0147872.ref108]\]                  0          149    ASR XL              Summit                                                                                                              Target                  Symptoms or patient willingness                                          Target                    Patients scheduled for revision with elevated metal ion levels and suspicion for ARMD   MRI                1                    3.3                  24                      0.161
  Langton 2011b \[[@pone.0147872.ref110]\]                    0          87     ASR XL              57 S-ROM, 30 Corail                                                                                                 All                                                                                              No                                                                                                                No                 2                    4.0                  25                      0.287
  Lavigne et al. 2011 (Arm 3) \[[@pone.0147872.ref113]\]      0          32     ASR XL              Trilock                                                                                                             All                                                                                              No                                                                                                                No                 2                    2.0                  0                       0.000
  Fernandez et al. 2014 (Arm 2) \[[@pone.0147872.ref035]\]    0          23     ASR XL              Proxima                                                                                                             All                                                                                              Target                    ns                                                                                      CT                 3                    2.9                  0                       0.000
  Reito et al. 2015 \[[@pone.0147872.ref117]\]                196        225    ASR XL              149 Summit, 53 Corail, 21 S-ROM, 1 Proxima                                                                          All                                                                                              All                                                                                                               MRI                4                    5.4                  73                      0.324
  Reito et al. 2013 (Arm 2) \[[@pone.0147872.ref079]\]        281        312    ASR XL              233 Summit, 54 Corail, 24 S-ROM, 1 Proxima                                                                          All                                                                                              All                                                                                                               MRI                4                    4.6                  96                      0.308
  Cip et al. 2014 \[[@pone.0147872.ref144]\]                  88         99     ASR XL              97 CoxaFit, 2 ARGE Geradschaft                                                                                      All                                                                                              All                                                                                                               CT                 4                    3.5                  26                      0.263
  Kostensalo et al. 2014 (Arm 2) \[[@pone.0147872.ref056]\]   0          39     BHR                 Synergy                                                                                                             Target                  ns                                                                       No                                                                                                                No                 1                    3.9                  0                       0.000
  Hosny et al. 2013 \[[@pone.0147872.ref107]\]                41         44     BHR                 Synergy                                                                                                             Target                  \"Some patients\"                                                        Target                    Patient with symptoms or elevated metal ion level (no cut-off stated)                   MRI                1                    5.0                  2                       0.045
  Lavigne et al. 2011 (Arm 4) \[[@pone.0147872.ref113]\]      0          29     BHR                 Anthology                                                                                                           All                                                                                              No                                                                                                                No                 2                    2.0                  0                       0.000
  Chatrath et al. 2013 \[[@pone.0147872.ref104]\]             88         89     Conserve+           Profemur                                                                                                            No                                                                                               No                                                                                                                No                 0                    2.5                  3                       0.034
  Levy et al. 2013 \[[@pone.0147872.ref114]\]                 0          66     Conserve+           Profemur                                                                                                            Target                  \"Patients with suspected failing hips\"                                 Target                    \"Patients with suspected failing hips\"                                                CT/US              1                    1.3                  7                       0.106
  Lardanchet et al. 2012 (Arm 3) \[[@pone.0147872.ref111]\]   0          20     Conserve+           16 Profemur L, 4 Contact Evolution                                                                                  All                                                                                              No                                                                                                                No                 2                    1.0                  0                       0.000
  Hasegawa et al. 2013 \[[@pone.0147872.ref106]\]             98         108    Cormet              Cti II                                                                                                              All                                                                                              All                                                                                                               MRI                4                    3.8                  5                       0.046
  Mertl et al. 2010 \[[@pone.0147872.ref115]\]                107        111    DUROM               78 Muller type, 28 Emeraude                                                                                         No                                                                                               No                                                                                                                No                 0                    2.5                  0                       0.000
  Berton et al. 2010 \[[@pone.0147872.ref101]\]               92         100    DUROM               Zweymuller SL                                                                                                       No                                                                                               No                                                                                                                No                 0                    4.8                  1                       0.010
  Saragaglia et al. 2015 \[[@pone.0147872.ref118]\]           165        177    DUROM               PF Stem                                                                                                             No                                                                                               Target                    Unexplained pain, osteolysis, bone cysts                                                US                 1                    6.7                  4                       0.023
  Lavigne et al. 2011 (Arm 1) \[[@pone.0147872.ref113]\]      0          42     DUROM               CLS Spotorno                                                                                                        All                                                                                              No                                                                                                                No                 2                    2.0                  1                       0.024
  Lardanchet et al. 2012 (Arm 1) \[[@pone.0147872.ref111]\]   0          24     DUROMTHA            20 Contact Evolution, 4 Profemur L                                                                                  All                                                                                              No                                                                                                                No                 2                    1.0                  2                       0.083
  Bayley et al. 2015 \[[@pone.0147872.ref100]\]               215        258    M2a-Magnum          Mallory Head                                                                                                        All                                                                                              Target                    Follow-up \>1 year                                                                      US                 3                    4.5                  0                       0.000
  Kostensalo et al. 2012 \[[@pone.0147872.ref109]\]           635        691    M2a-Magnum/ReCap    Bimetric                                                                                                            No                                                                                               No                                                                                                                No                 0                    1.0                  0                       0.000
  Latteier et al. 2011 (Arm 2) \[[@pone.0147872.ref112]\]     0          487    M2a-Magnum/ReCap    ns                                                                                                                  No                                                                                               No                                                                                                                No                 0                    5.0                  3                       0.006
  Lardanchet et al. 2012 (Arm 2) \[[@pone.0147872.ref111]\]   0          23     M2a-Magnum/ReCap    Exception                                                                                                           All                                                                                              No                                                                                                                No                 2                    1.0                  0                       0.000
  Lavigne et al. 2011 (Arm 2) \[[@pone.0147872.ref113]\]      0          34     M2a-Magnum/ReCap    Taperloc                                                                                                            All                                                                                              No                                                                                                                No                 2                    2.0                  0                       0.000
  Sturup et al. 2012 (Arm 2) \[[@pone.0147872.ref120]\]       0          271    M2a-Magnum/ReCap    ns                                                                                                                  All                                                                                              Target                    Patients with symptoms                                                                  CT                 3                    3.5                  1                       0.004
  Bosker et al. 2012 \[[@pone.0147872.ref103]\]               119        120    M2a-Magnum/ReCap    Bimetric                                                                                                            All                                                                                              All                                                                                                               CT                 4                    3.6                  13                      0.108
  Mokka et al. 2013 \[[@pone.0147872.ref116]\]                74         80     M2a-Magnum/ReCap    BiMetric                                                                                                            All                                                                                              All                                                                                                               MRI                4                    6.0                  3                       0.038
  Kostensalo et al. 2014 (Arm 3) \[[@pone.0147872.ref056]\]   0          41     R3                  Synergy                                                                                                             Target                  ns                                                                       No                                                                                                                No                 1                    2.3                  2                       0.049
  Dramis et al. 2014 \[[@pone.0147872.ref105]\]               46         50     R3                  30 Anthology, 18 CPCS, 2 SL Plus                                                                                    All                                                                                              Target                    Symptomatic patients and those with \"adverse investigations\"                          MRI                3                    3.8                  12                      0.240
  MD THR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Latteier et al. 2011 (Arm 1) \[[@pone.0147872.ref112]\]     0          750    M2a-38              ns                                                                                                                  No                                                                                               No                                                                                                                No                 0                    5.0                  11                      0.015
  Sturup et al. 2012 (Arm 1) \[[@pone.0147872.ref120]\]       0          85     M2a-38              ns                                                                                                                  All                                                                                              Target                    Patients with symptoms                                                                  CT                 3                    3.5                  0                       0.000
  Smeekes et al. 2015 \[[@pone.0147872.ref129]\]              351        377    M2a-38              Taperloc                                                                                                            All                                                                                              Target                    Patients with symptoms, Co or Cr level \>5 ppb                                          MRI                3                    2.5                  51                      0.135
  Barret et al. 2012 \[[@pone.0147872.ref122]\]               0          779    Pinnacle            310 Summit Porocoat, 234 S-ROM, 139 Summit Duofix, 47 Prodigy, 35 AML, 11 Summit Cemented, 2 Replica, 1 Endurance   No                                                                                               No                                                                                                                No                 0                    4.2                  8                       0.010
  Kindsfater et al. 2012 \[[@pone.0147872.ref125]\]           0          95     Pinnacle            86 S-ROM, 8 Summit Cemented, 1 Summit                                                                               No                                                                                               No                                                                                                                No                 0                    6.0                  0                       0.000
  Engh et al. 2010 \[[@pone.0147872.ref124]\]                 126        131    Pinnacle            AML/Prodigy (numbers ns)                                                                                            No                                                                                               No                                                                                                                No                 0                    5.6                  0                       0.000
  Whitehouse et al. 2013 \[[@pone.0147872.ref094]\]           0          99     Pinnacle            Corail                                                                                                              No                                                                                               No                                                                                                                No                 0                    4.0                  3                       0.030
  Bernasek et al. 2013 \[[@pone.0147872.ref123]\]             0          354    Pinnacle            Summit                                                                                                              No                                                                                               No                                                                                                                No                 0                    6.8                  0                       0.000
  Schouten et al. 2012 \[[@pone.0147872.ref128]\]             0          34     Pinnacle            Corail                                                                                                              All                                                                                              No                                                                                                                No                 2                    1.0                  0                       0.000
  Matharu et al. 2014 \[[@pone.0147872.ref127]\]              511        578    Pinnacle            Corail                                                                                                              All                                                                                              Target                    Co or Cr level \>7 ppb                                                                  MRI/US             3                    5.0                  17                      0.029
  Lainiala et al. 2014 \[[@pone.0147872.ref126]\]             430        371    Pinnacle System     398 Summit, 17 Corail, 14 S-ROM, 1 Prodigy                                                                          All                                                                                              Target                    Patients with symptoms, Co or Cr level \>5 ppb                                          MRI                3                    7.5                  32                      0.086

10.1371/journal.pone.0147872.t002

###### Summary data of the study arms.
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  ------------------------- ------------------------------------------------ -------------------------------------------------- ----
  **Implant used**          **Study arms**                                                                                      
                            Hip resurfacing (HR)                                                                                
                                                                             BHR                                                48
                                                                             Conserve+                                          18
                                                                             ASR                                                13
                                                                             DUROM                                              5
                                                                             Cormet                                             5
                                                                             Recap---M2a-Magnum                                 5
                                                                             Birmingham Mid Head Resection                      2
                                                                             Cormet Uncemented                                  2
                                                                             Bionic                                             1
                                                                             McMinn                                             1
                            Large-diameter total hip replacements (LD-THA)                                                      
                                                                             ASR XL--Mixed stems                                10
                                                                             DUROM--Mixed stems                                 5
                                                                             ReCap-M2a-Magnum---Mixed stems                     8
                                                                             BHR--Mixed stems                                   3
                                                                             R3 --Mixed stems                                   2
                                                                             Conserve+---Mixed stems                            2
                                                                             Adept/BHR---CPT                                    1
                                                                             Cormet--Cti II                                     1
                                                                             Adept---CPT                                        1
                            Medium-diameter total hip replacement (MD-THA)                                                      
                                                                             Pinnacle--Mixed stems                              8
                                                                             M2a-38 --Mixed stems                               3
  **Screening method**      **Study arms**                                                                                      
                            Level 0                                                                                             
                                                                             None                                               76
                            Level 1                                                                                             
                                                                             Targeted blood metal ions without imaging          8
                                                                             Targeted imaging without blood metal ions          3
                                                                             Targeted blood metal ions with targeted imaging    9
                            Level 2                                                                                             
                                                                             Blood metal ions without imaging                   26
                                                                             Cross-sectional imaging without blood metal ions   1
                            Level 3                                                                                             
                                                                             Blood metal ions with targeted imaging             11
                            Level 4                                                                                             
                                                                             Blood metal ions AND cross-sectional imaging       10
  **Year of publication**   **Study arms**                                                                                      
                                                                             2005                                               1
                                                                             2006                                               1
                                                                             2007                                               1
                                                                             2008                                               8
                                                                             2009                                               12
                                                                             2010                                               11
                                                                             2011                                               31
                                                                             2012                                               23
                                                                             2013                                               23
                                                                             2014                                               24
                                                                             2015                                               9
  **Follow-up time**        **Study arms**                                                                                      
                                                                             ≤2 years                                           23
                                                                             2--4 years                                         51
                                                                             4--6 years                                         43
                                                                             6--8 years                                         15
                                                                             \>8 years                                          12
  ------------------------- ------------------------------------------------ -------------------------------------------------- ----

The total overall pooled estimate for the prevalence of revision confirmed ARMD among 145 study arms was 1.07% (CI: 0.69--1.49, I^2^ = 92.3%, p~heterogeneity~ \< 0.001). In general, the amount of heterogeneity was high. Individual study arms were stratified according to the level of screening for ARMD and the implant concept. The individual weighted prevalences of ARMD in each study arm under the random effects model are shown in Figs [2](#pone.0147872.g002){ref-type="fig"}--[4](#pone.0147872.g004){ref-type="fig"}. In the hip-resurfacing group, the overall pooled prevalence of ARMD was 0.43% (CI: 0.25--0.65). With more comprehensive screening, the higher pooled prevalence of ARMD was observed ([Fig 2](#pone.0147872.g002){ref-type="fig"}). In the LD THR group, the overall pooled prevalence of ARMD was 4.6% (CI: 1.94--8.32). Prevalence peaked in the study arms with Level 4 screening ([Fig 3](#pone.0147872.g003){ref-type="fig"}). The clear trend of higher prevalence of ARMD associated with an increased level of screening seen among resurfacings groups was not observed in this group. The overall pooled prevalence of revision confirmed ARMD in the MD THR group was 1.43% (CI: 0.21--3.70%). This group lacked study arms with Level 1 and Level 4 screening ([Fig 4](#pone.0147872.g004){ref-type="fig"}).

![Forest plot of prevalence of ARMD in the HR group stratified by level of screening.](pone.0147872.g002){#pone.0147872.g002}

![Forest plot of prevalence of ARMD in the LD THA group stratified by level of screening.](pone.0147872.g003){#pone.0147872.g003}

![Forest plot of prevalence of ARMD in the MD THR group stratified by level of screening.](pone.0147872.g004){#pone.0147872.g004}

Metaregression analysis {#sec010}
-----------------------

Metaregression was performed separately for hip resurfacings and LD THRs ([Table 3](#pone.0147872.t003){ref-type="table"}). Metaregression was not performed in the MD THR group since no study arms were available for screening levels 1 and 4. For hip resurfacings, comprehensive screening (Level 4) was superior when compared with other levels, i.e., the prevalence of revision confirmed ARMD was significantly higher in level 4 studies when compared with others. An increase in follow-up time had a small, positive effect on the prevalence of ARMD. This association remained after adjusting for confounding variables. In the LD THR group, level 1 screening proved to be as good as level 4 screening. Screening levels 0.2 and 3 were inferior when compared with level 4 screening, i.e., the prevalence of ARMD was significantly lower in these levels compared with the level 4 study arms. These differences remained after adjusting for confounding variables.

10.1371/journal.pone.0147872.t003

###### Results of the metaregression analysis in the HR and LD THR groups.
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  -------------------------------------- ---------------------------------------------------- ------------ ------- --------- ----------- ------- ---------
  **Univariate regression analysis**     **Hip resurfacings**                                 **LD-THA**                                         
                                                                                              β            SE      p-value   β           SE      p-value
  **Screening**                          Comprehensive (Level 4)                              Reference    \-      \-        Reference   \-      \-
                                         Blood metal ions with targeted imaging (Level 3)     -0.117       0.051   0.022     -0.279      0.098   0.005
                                         Blood metal ions without imaging (Level 2)           -0.221       0.037   \<0.001   -0.259      0.082   0.002
                                         Targeted Blood metal ions and/or imaging (Level 1)   -0.212       0.037   \<0.001   -0.150      0.082   0.067
                                         No screening (Level 0)                               -0.273       0.034   \<0.001   -0.329      0.086   \<0.001
  **Multivariate regression analysis**   **Hip resurfacings**                                 **LD-THA**                                         
                                                                                              β            SE      p-value   β           SE      p-value
  **Screening**                          Comprehensive (Level 4)                              Reference    \-      \-        Reference   \-      \-
                                         Blood metal ions with targeted imaging (Level 3)     -0.137       0.051   0.007     -0.264      0.108   0.014
                                         Blood metal ions without imaging (Level 2)           -0.213       0.036   \<0.001   -0.245      0.115   0.033
                                         Targeted CoCr and/or imaging (Level 1)               -0.220       0.037   \<0.001   -0.141      0.090   0.12
                                         No screening (Level 0)                               -0.261       0.034   \<0.001   -0.320      0.117   0.006
  **Mean FU**                            Per one year                                         0.0054       0.003   0.045     -0.013      0.02    0.5
  **Publication year**                   Per one year                                         0.0034       0.003   0.3       -0.006      0.03    0.8
  -------------------------------------- ---------------------------------------------------- ------------ ------- --------- ----------- ------- ---------

β = unstandardized regression coefficient, SE = standard error.

Sensitivity analysis {#sec011}
--------------------

All analyses were calculated using only study arms with Birmingham Hip Resurfacing, which has been the most used implant (48 arms). A trend was observed that showed an increased prevalence of ARMD associated with an increased level of screening ([Fig 5](#pone.0147872.g005){ref-type="fig"}). The results of the metaregression analyses were similar to those observed with all hip resurfacings with the exception of level 3, where no inferiority to level 4 screening was observed ([Table 4](#pone.0147872.t004){ref-type="table"}). Screening levels 0,1 and 2 were significantly inferior to level 4.

![Forest plot of prevalence of ARMD in the BHR group stratified by level of screening.](pone.0147872.g005){#pone.0147872.g005}

10.1371/journal.pone.0147872.t004

###### Results of the metaregression analysis in the BHR.
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  -------------------------------------- ---------------------------------------------------- ----------- ------- ---------
  **Univariate regression analysis**     **Birmingham Hip Resurfacing**                                           
                                                                                              β           SE      p-value
  **Screening**                          Comprehensive (Level 4)                              Reference   \-      \-
                                         Blood metal ions with targeted imaging (Level 3)     -0.064      0.061   0.3
                                         Blood metal ions without imaging (Level 2)           -0.169      0.051   0.001
                                         Targeted CoCr and/or imaging (Level 1)               -0.141      0.051   0.006
                                         No screening (Level 0)                               -0.212      0.048   \<0.001
  **Multivariate regression analysis**   **All study arms**                                                       
                                                                                              β           SE      p-value
  **Screening**                          Comprehensive (Level 4)                              Reference   \-      \-
                                         Blood metal ions with targeted imaging (Level 3)     -0.64       0.90    0.2
                                         Blood metal ions without imaging (Level 2)           -2.06       0.75    0.001
                                         Targeted Blood metal ions and/or imaging (Level 1)   -1.51       0.74    0.003
                                         No screening (Level 0)                               -1.94       0.67    \<0.001
  **Mean FU**                            Per one year                                         0.012       0.068   0.2
  **Publication year**                   Per one year                                         0.14        0.10    0.2
  -------------------------------------- ---------------------------------------------------- ----------- ------- ---------

β = unstandardized regression coefficient, SE = standard error.

Discussion {#sec012}
==========

Despite the marginal use of MoM hip replacements nowadays, the orthopedic community must bear the burden of a vast follow-up that has resulted from the widespread use of these devices over the past 15 years \[[@pone.0147872.ref130]\]. It is evident that patients with MoM hip replacements must be followed-up, at least clinically. However, there is paucity of information available regarding the optimal follow-up protocol and especially regarding the use of blood metal ion measurement and cross-sectional imaging. We must be rigorous and aim for the best possible and up-to-date evidence when constructing guidelines on how to manage patients with MoM replacements. Thus, we have performed a systematic literature review and meta-analysis to investigate the influence of the extent of the screening protocol on the prevalence of revision confirmed ARMD.

The overall pooled prevalence of confirmed prevalance ARMD was low. This is not a surprising finding considering that in most of the studies no screening was implemented other than conventional x-rays and clinical examination. The prevalence of ARMD was lowest in the study arms without screening (level 0). Moreover, these study arms also included the largest number of hips. Due to the weighting based on the sample sizes, the overall prevalence of ARMD does not, therefore, correctly highlight the current situation in patients with MoM hip replacements.

Heterogeneity between the studies was high. Firstly, there was a lot of variation in the implants used. There are many implant specific factors (clearance, hemispherity, carbon content, etc) that influence the wear of the bearing surface, and, therefore, bearing wear rates may differ greatly between different bearing systems \[[@pone.0147872.ref131],[@pone.0147872.ref132]\]. Furthermore, both clinical studies and registry data show that there are major differences in the failure rates between different hip resurfacings and LD THRs \[[@pone.0147872.ref079],[@pone.0147872.ref110],[@pone.0147872.ref133]\]. These differences in failure rates are due to the modular taper-trunnion junction between the head and stem in the THRs, which is an additional source of metal debris due to corrosion and mechanical wear in the taper interface \[[@pone.0147872.ref134]\]. Secondly, when only study arms with the BHR implant were analyzed, high heterogeneity was still observed. The outcome variable assessed in our analysis was the revision rate for ARMD. Even if two studies implemented identical screening protocols, i.e., full coverage blood metal ion measurement and targeted cross-sectional imaging, very different prevalences of revision confirmed ARMD could still be observed. This is because indications for revision surgery can vary greatly between different surgeons and different hospitals. Some surgeons may prefer closer follow-up in cases where others would prefer revision surgery. The current literature lacks a specific definition for ARMD and especially the indications for revision. Due to these implant and inter-observer related differences, a high heterogeneity is observed.

Other confounding factors that may have influenced the observed prevalence of revision confirmed ARMD are the follow-up time and the publication year of the study. The prevalence of ARMD increases in a cumulative manner with increasing follow-up time \[[@pone.0147872.ref110]\]. ARMD may manifest as early as two years postoperatively and a late occurrence after ten-years of follow-up is also possible \[[@pone.0147872.ref002],[@pone.0147872.ref015]\]. Thus, we included follow-up time as a confounding variable in our metaregression analysis to investigate whether prevalence of ARMD is a matter of long enough follow-up time or a matter of the screening protocol used. The follow-up time had no influence on the observed prevalence of ARMD. Therefore, our results suggests that even if the prevalence of revision confirmed ARMD would increase with increasing follow-up time, this association would not be observed due to the stronger effect of the screening protocol used.

The year of publication was also an important variable to consider as a confounder. We believe that there has been considerable publication bias in the MoM literature during recent years. As a result, there has been a strong tendency to publish as high as possible prevalences of pseudotumours and ARMD. Several extremely poorly functioning MoM hip replacements in have been in widespread use, and during the last two years numerous studies have been published that report the outcome of these poorly functioning implants. In most of the studies, the primary aim has been to elucidate the higher than anticipated failure rate due to ARMD. The "higher than anticipated" failure rate reflects the actual situation that we are facing nowadays with several MoM hip replacements, but from the perspective of the literature review we are facing publication bias. We do not have a sufficient number of studies where novel screening methods have not been used (level 0) and that report the results of the use of MoM hip replacements before the problems with MoM bearings surfaces became evident and blood metal ion measurements and cross-sectional imaging became popular. Moreover, prior to 2010, MoM hip replacements were popular and there was a trend towards positive results instead. The trend towards positive results can be observed in the numerous studies that report favorable results with the BHR device. Furthermore, to support this statement, one can see that there are no studies prior to 2010 that have reported, for example, the results of the ASR XL THR, which was eventually shown to have been disastrous \[[@pone.0147872.ref079],[@pone.0147872.ref110],[@pone.0147872.ref117]\]. As was the case with follow-up time, we did not observe any influence of the year of publication on the observed prevalence of ARMD. Therefore, our results reliably highlight the important role that the screening protocol has in influencing the prevalence of ARMD.

In the hip-resurfacing group, metaregression analysis suggested that level 4 screening was superior to all other screening levels and especially when compared to level 3. We consider this to be a novel finding. The main difference between these screening protocols is that when changing from level 3 to level 4, we ought to refer many patients with non-elevated metal ion levels or without complaints for cross-sectional imaging since these patients are not imaged in level 3 screening. We observed slightly higher pooled prevalence of revision confirmed ARMD in study arms with level 4 screening compared with study arms with level 3 screening. This difference in pooled estimate for the prevalence of ARMD is one benefit of screening patients without relevant clinical findings.

Our results suggest that this movement from targeted imaging to full coverage imaging is useful with regard to the prevalence of revision confirmed ARMD. However, the economical aspect and cost-effectiveness of this "transition" should be carefully assessed. When only BHR implants were analyzed, level 3 screening was not found to be inferior to level 4 screening. This would indicate that full coverage imaging would not be beneficial in patients with BHR. However, in this subgroup the analysis might be underpowered. These results should be kept in mind especially when the economics of the surveillance of patients with MoM hip replacements are considered since cross-sectional imaging is the most expensive procedure in the screening process.

In contrast to imaging, especially MRI, metal ion measurement is a readily available, inexpensive screening modality that should be used in the surveillance of patients with MoM hip replacements \[[@pone.0147872.ref015]\]. Current MHRA guidelines do not give instructions on how to perform metal ion measurement in asymptomatic patients with MoM hip resurfacing \[[@pone.0147872.ref135]\]. In our institution, however, metal ion measurement is a routine follow-up measure in all hip-resurfacing patients. As our previous study suggests, the measurement of metal ions is beneficial in patients without complaints since ARMD is often seen in asymptomatic patients \[[@pone.0147872.ref015]\]. The results of our current study also imply the usefulness of routine metal ion measurement. A comparision of the non-routine metal ion measurement (level 1) with the routine measurement (level 3) would have been more sensible from this point of view, but for the sake of simplicity we used level 4 as our reference in our metaregression analysis. It should be noted, however, that confidence intervals for pooled prevalences of revision confirmed ARMD in the level 1 and level 2 screening study arms barely overlap with those seen in the level 3 study arms. Moreover, a distinct change in the prevalence of ARMD is seen when moving from screening levels 1--2 to screening levels 3--4. To conclude, our results suggest that routine metal ion measurement is useful in patients with hip resurfacing or BHR. More importantly, routine metal ion measurement should be performed along with targeted or full coverage imaging.

Results in the LD THR group were different than those in the hip-resurfacing group. Surprisingly, level 1 screening was equal to level 4 screening. Moreover, the pooled prevalence of ARMD with level 2 and 3 screening was clearly smaller than in study arms with level 1 screening. This is probably a biased result due to sample sizes since most study arms in level 2 screening included less than 40 hips, and these numbers might be too small to detect the actual failure rate. However, in study arms with level 3 screening there were two cohorts with more than 250 hips, and surprisingly a small prevalence of ARMD was observed in these study arms. For example, Bayley et al. had no revision due to ARMD after extensive screening \[[@pone.0147872.ref100]\].

The major issue with LD THRs is taper corrosion that may possibly release more toxic wear debris than that originating from the bearing surfaces \[[@pone.0147872.ref134]\]. Most probably, severe ARMD may be observed even in the presence of non-elevated (\< 5 ppb) metal ion levels as a result. This would also explain why the clearly highest prevalence of ARMD was seen in the study arms with level 4 screening, i.e., in those studies where all patients were screened with cross-sectional imaging independent of blood metal ion levels. Hence, in patients with LD THRs, a low threshold for imaging is recommended even in the presence of normal metal ion levels.

Conclusions {#sec013}
===========

The aims of this study were successfully achieved. Based on our systematic literature review and metaregression analysis, the overall pooled prevalence of revision confirmed ARMD represented in the current MoM literature is low. However, this seems to be a consequence of the use of the conventional follow-up protocol, namely x-rays and clinical examination, in the majority of the published studies. The implementation of the novel screening protocol results in a clearly higher prevalence of ARMD. The highest prevalence of revision confirmed ARMD was seen when all patients had undergone both blood metal ion measurement and cross-sectional imaging. These outcomes were irrespective of the follow-up time or study publication year. With regard to hip resurfacings, routine cross-sectional imaging regardless of clinical findings is advisable. Moreover, targeted metal ion measurement and/or imaging are not sufficient in the screening for ARMD in any implant concept. However, economical aspects should be considered when choosing the preferred screening level.
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